IMCR Q4 2024 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena

IMCRImmunocore Holdings plc

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$84M+18.8% YoY

Gross Profit

$84M99.6% margin

Operating Income

-$19M-23.1% margin

Net Income

-$24M-28.3% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+4.7%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$18M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$649M

Stockholders' Equity

$361M

Cash & Equivalents

$456M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$84M	$71M	+18.8%
Gross Profit	$84M	$71M	+18.6%
Operating Income	-$19M	-$17M	-13.1%
Net Income	-$24M	-$20M	-19.4%

Revenue Segments

Sale of Therapies

$84M100%